Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 152

1.

Tumor cell alpha-N-acetylgalactosaminidase activity and its involvement in GcMAF-related macrophage activation.

Mohamad SB, Nagasawa H, Uto Y, Hori H.

Comp Biochem Physiol A Mol Integr Physiol. 2002 May;132(1):1-8.

PMID:
12062184
2.

Antitumor effect of vitamin D-binding protein-derived macrophage activating factor on Ehrlich ascites tumor-bearing mice.

Koga Y, Naraparaju VR, Yamamoto N.

Proc Soc Exp Biol Med. 1999 Jan;220(1):20-6.

PMID:
9893164
4.
5.
6.

Immunotherapy of metastatic colorectal cancer with vitamin D-binding protein-derived macrophage-activating factor, GcMAF.

Yamamoto N, Suyama H, Nakazato H, Yamamoto N, Koga Y.

Cancer Immunol Immunother. 2008 Jul;57(7):1007-16. Retraction in: Cancer Immunol Immunother. 2014 Dec;63(12):1349.

7.
9.

Deglycosylation of serum vitamin D3-binding protein leads to immunosuppression in cancer patients.

Yamamoto N, Naraparaju VR, Asbell SO.

Cancer Res. 1996 Jun 15;56(12):2827-31.

10.
12.

Gc protein-derived macrophage activating factor (GcMAF): isoelectric focusing pattern and tumoricidal activity.

Mohamad SB, Nagasawa H, Sasaki H, Uto Y, Nakagawa Y, Kawashima K, Hori H.

Anticancer Res. 2003 Nov-Dec;23(6a):4451-7.

PMID:
14666733
13.

Immunotherapy of HIV-infected patients with Gc protein-derived macrophage activating factor (GcMAF).

Yamamoto N, Ushijima N, Koga Y.

J Med Virol. 2009 Jan;81(1):16-26. doi: 10.1002/jmv.21376. Retraction in: J Med Virol. 2014 Nov;86(11):1998.

14.

Serum alpha-N-acetylgalactosaminidase is associated with diagnosis/prognosis of patients with squamous cell carcinoma of the uterine cervix.

Reddi AL, Sankaranarayanan K, Arulraj HS, Devaraj N, Devaraj H.

Cancer Lett. 2000 Sep 29;158(1):61-4.

PMID:
10940510
16.

Gc protein (vitamin D-binding protein): Gc genotyping and GcMAF precursor activity.

Nagasawa H, Uto Y, Sasaki H, Okamura N, Murakami A, Kubo S, Kirk KL, Hori H.

Anticancer Res. 2005 Nov-Dec;25(6A):3689-95. Review.

17.

Degalactosylated/desialylated human serum containing GcMAF induces macrophage phagocytic activity and in vivo antitumor activity.

Kuchiike D, Uto Y, Mukai H, Ishiyama N, Abe C, Tanaka D, Kawai T, Kubo K, Mette M, Inui T, Endo Y, Hori H.

Anticancer Res. 2013 Jul;33(7):2881-5.

PMID:
23780974
18.

GC protein-derived macrophage-activating factor decreases α-N-acetylgalactosaminidase levels in advanced cancer patients.

Thyer L, Ward E, Smith R, Branca JJ, Morucci G, Gulisano M, Noakes D, Eslinger R, Pacini S.

Oncoimmunology. 2013 Aug 1;2(8):e25769. Epub 2013 Jul 29.

19.

Gc protein-derived macrophage-activating factor (GcMAF) stimulates cAMP formation in human mononuclear cells and inhibits angiogenesis in chick embryo chorionallantoic membrane assay.

Pacini S, Morucci G, Punzi T, Gulisano M, Ruggiero M.

Cancer Immunol Immunother. 2011 Apr;60(4):479-85. doi: 10.1007/s00262-010-0953-7. Epub 2010 Dec 14.

PMID:
21170647
20.

Supplemental Content

Support Center